Citadel Advisors’s DataMeds AI, Inc. Common Stock MEDS Stock Holding History

Citadel Advisors’s Portfolio MEDS Stock Details MEDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-596	Closed	-$129K	–	15708
2025 Q1	$129K	Buy	+596	New	+$101K	﹤0.01%	11105

Other funds holding MEDS

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VFIC

Valley Forge Investment Consultants Audubon, Pennsylvania $334M AUM 17.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $5.64B AUM

Citadel Advisors's MEDS Position: Q2 2025 in Review

Citadel Advisors sold out of DataMeds AI, Inc. Common Stock (MEDS) in Q2 2025, closing a stake of 596 shares — an estimated $129K sold.

Citadel Advisors first reported a position in MEDS in Q1 2025 and held it in 1 quarter. The position peaked at $129K in Q1 2025. 6 funds tracked by Wall St. Rank hold MEDS as of Q2 2025.

Citadel Advisors reported no remaining DataMeds AI, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 596 DataMeds AI, Inc. Common Stock shares in Q2 2025, an estimated $129K.
Citadel Advisors first reported a position in DataMeds AI, Inc. Common Stock in Q1 2025 and held it in 1 quarter.
Citadel Advisors's DataMeds AI, Inc. Common Stock position peaked at $129K in Q1 2025.
6 funds tracked by Wall St. Rank held DataMeds AI, Inc. Common Stock as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.